Trial · NCT02125461
Results by group49
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 49
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) | Durvalumab (MEDI4736) | 16.8 | 95% Confidence Interval 13.0 to 18.1 | Months | |
| Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) | Placebo | 5.6 | 95% Confidence Interval 4.6 to 7.8 | Months | |
| Overall Survival | Durvalumab (MEDI4736) | NA | 95% Confidence Interval 34.7 to NA | Months | |
| Overall Survival | Placebo | 28.7 | 95% Confidence Interval 22.9 to NA | Months | |
| Objective Response Rate (ORR) Based on BICR Assesments According to RECIST 1.1 | Durvalumab (MEDI4736) | 30.0 | 95% Confidence Interval 25.79 to 34.53 | Percentage of patients | |
| Objective Response Rate (ORR) Based on BICR Assesments According to RECIST 1.1 | Placebo | 17.8 | 95% Confidence Interval 12.95 to 23.65 | Percentage of patients | |
| Duration of Response (DoR) Based on BICR Assessments According to RECIST 1.1 | Durvalumab (MEDI4736) | NA | 95% Confidence Interval 27.4 to NA | Months | |
| Duration of Response (DoR) Based on BICR Assessments According to RECIST 1.1 | Placebo | 18.4 | 95% Confidence Interval 6.7 to 24.5 | Months | |
| Proportion of Patients Alive and Progression Free at 12 Months From (APF12) Based on BICR Assessments According to RECIST 1.1 | Durvalumab (MEDI4736) | 55.9 | 95% Confidence Interval 51.0 to 60.4 | Percentage of patients | |
| Proportion of Patients Alive and Progression Free at 12 Months From (APF12) Based on BICR Assessments According to RECIST 1.1 | Placebo | 35.3 | 95% Confidence Interval 29.0 to 41.7 | Percentage of patients | |
| Proportion of Patients Alive and Progression Free at 18 Months From (APF18) Based on BICR Assessments According to RECIST 1.1 | Durvalumab (MEDI4736) | 44.2 | 95% Confidence Interval 37.7 to 50.5 | Percentage of patients | |
| Proportion of Patients Alive and Progression Free at 18 Months From (APF18) Based on BICR Assessments According to RECIST 1.1 | Placebo | 27.0 | 95% Confidence Interval 19.9 to 34.5 | Percentage of patients | |
| Time to Death or Distant Metastasis (TTDM) Based on BICR Assessments According to RECIST 1.1 | Durvalumab (MEDI4736) | 28.3 | 95% Confidence Interval 24.0 to 34.9 | Months | |
| Time to Death or Distant Metastasis (TTDM) Based on BICR Assessments According to RECIST 1.1 | Placebo | 16.2 | 95% Confidence Interval 12.5 to 21.1 | Months | |
| Percentage of Patients Alive at 24 Months (OS24) | Durvalumab (MEDI4736) | 66.3 | 95% Confidence Interval 61.7 to 70.4 | Percentage of patients | |
| Percentage of Patients Alive at 24 Months (OS24) | Placebo | 55.6 | 95% Confidence Interval 48.9 to 61.8 | Percentage of patients | |
| Time to Second Progression or Death (PFS2) | Durvalumab (MEDI4736) | 28.3 | 95% Confidence Interval 25.1 to 34.7 | Months | |
| Time to Second Progression or Death (PFS2) | Placebo | 17.1 | 95% Confidence Interval 14.5 to 20.7 | Months | |
Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL), Assessed Using European Organization for Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30) | Durvalumab (MEDI4736) | 7.4 | 95% Confidence Interval 5.5 to 9.3 | Months | |
Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL), Assessed Using European Organization for Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30) | Placebo | 5.7 | 95% Confidence Interval 4.2 to 10.5 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02125461/results